Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.20 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 8%. A quarter ago, it was expected that this company would post a loss of $0.27 per share when it actually produced a loss of $0.21, delivering a surprise of 22.22%. Over the last four quarters, the company has surp ...

In March 2024, Immunovant was awarded U.S. Patent No. 11,926,669 covering composition of matter of IMVT-1402 and its binding sequence to FcRn, method of use of the antibody for treating autoimmune disease, and methods for its manufacturing. Not including any potential patent term extension, the issued composition-of-matter patent term will extend until June 2043. • Dermavant: For the fourth quarter and fiscal year ended March 31, 2024, Roivant reported VTAMA net product revenue of $19.3M, and $75.1M, respec ...

BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update. Once-daily brepocitinib produced the best Treatment Failure rates observed to date among studies in active non-infectious uveitis (NIU), supporting initiation of a pivotal program in NIU in the second half of calendar year 2024 Brepocitinib is well positioned to support a potential ...

BASEL, Switzerland and LONDON and NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 30, 2024, to report its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Present ...

BASEL, Switzerland and LONDON and NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 30, 2024, to report its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Present ...

Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2023 Results Conference Call February 13, 2024 8:00 AM ET Company Participants Stephanie Lee - Vice President, Special Projects Matt Gline - Chief Executive Officer Mayukh Sukhatme - President and Chief Investment Officer Richard Pulik - Chief Financial Officer Frank Torti - Managing Director, Vant Chair Conference Call Participants Allison Bratzel - Piper Sandler David Risinger - Leerink Partners Brian Cheng - JPMorgan Joyce Zhou - TD Cowen Dennis Ding - Jefferies Lou ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40782 ROIVANT SCIENCES LTD. (Exact name of Registrant as specified in its Charter) Bermuda 98-1173944 (State or other jurisdiction of incorporation or organiz ...

gorodenkoff Roivant Sciences Ltd. (NASDAQ:ROIV) is a pioneering biotech focused on inflammation and immunology that operates with an innovative business model through its subsidiaries. Each company in the Roivant family specializes in specific therapeutic areas such as immuno-dermatology, autoimmune disorders, RNA therapies, blood diseases, clinical trials intelligence, and AI for drug discovery and development. Notable achievements for this company are the lucrative sale of Telavant to Roche, the successfu ...

Financial Data and Key Metrics Changes - The company reported revenues of $18.4 million for the quarter, with a modest increase in GTN yield to 27.6% [19][23] - Pro forma cash and cash equivalents are expected to reach $7 billion following the sale of Telavant to Roche, marking a strong capital position for the company [9][23] Business Line Data and Key Metrics Changes - The VTAMA launch is progressing steadily, although at a slower pace than desired, with expectations for growth in the atopic dermatitis market in the second half of 2024 [37][39] - The anti-FcRn franchise, including Batoclimab and IMVT-1402, is showing promising clinical data, with ongoing mid-stage trials expected to validate the IgG suppression hypothesis [12][14] Market Data and Key Metrics Changes - The company is focusing on the intertriginous psoriasis market, reporting strong data that positions it competitively against other treatments [20][21] - The upcoming launch of VTAMA for atopic dermatitis is anticipated to significantly increase the patient population and market share [38] Company Strategy and Development Direction - The company aims to be patient and strategic in capital deployment, focusing on high-value opportunities rather than rushing into transactions [10][45] - There is a strong emphasis on maximizing the value of the FcRn program, which is seen as a potential cornerstone for future growth [88] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming data releases and the potential for significant growth in various therapeutic areas, particularly Graves' disease and SLE [40][94] - The company is committed to maintaining a strong pipeline and is exploring various strategic options to leverage its capital effectively [11][55] Other Important Information - The planned sale of Telavant to Roche for $7.1 billion upfront, with additional milestone payments, is a transformative opportunity for the company [8][9] - The company is actively working on enhancing its commercialization strategies to improve patient access and experience [26][84] Q&A Session Summary Question: What are the prospects for VTAMA scripts and potential growth drivers? - Management acknowledged that VTAMA scripts have flattened but expressed hope for growth ahead of the atopic dermatitis label addition in late 2024 [25][44] Question: How does the company balance capital deployment with the pressure to invest quickly? - Management emphasized the importance of patience in capital deployment, ensuring that investments are made in high-value opportunities rather than rushing into decisions [45][53] Question: What is the market opportunity for Graves' disease? - Management highlighted the significant unmet need in uncontrolled Graves' disease patients, indicating a large potential market for new therapeutic agents [63][64] Question: How does the company plan to compete in a crowded market? - Management stated that the company will focus on capital efficiency and strategic positioning to compete effectively in various indications [59][61] Question: What are the expectations for the upcoming Graves' disease data? - Management indicated that a normalization of thyroid hormone levels in about 50% of patients would be considered clinically meaningful [94]

November 13, 2023 Matthew Gline Chief Executive Officer Richard Pulik Chief Financial Officer Frank Torti, MD Vant Chair Eric Venker, MD, PharmD President and Chief Operating Officer Mayukh Sukhatme, MD President and Chief Investment Officer Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than st ...